204327-96-8

Basic information

• Product Name: (S)-N4-BENZYL-2-BENZYLPIPERAZINE
• Synonyms: (S)-N4-BENZYL-2-BENZYLPIPERAZINE;1,3-DIBENZYLPIPERAZINE;(S)-1,3-Dibenzylpiperazine;C-1161;(3S)-1,3-Dibenzylpiperazine;1-Benzyl-3(S)-benzylpiperazine;(3S)-1,3-bis(phenylmethyl)-Piperazine;(3S)-1,3-Bis(phenylmethyl)piperazine,99%e.e.
• CAS NO: 204327-96-8
• Molecular Formula: C₁₈H₂₂N₂
• Molecular Weight: 266.38
• Mol File: 204327-96-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 391.5°C at 760 mmHg
• Flash Point: 149.1°C
• Appearance: /
• Density: 1.064
• Vapor Pressure: 2.45E-06mmHg at 25°C
• Refractive Index: 1.583
• PKA: 9.25±0.40(Predicted)
• CAS DataBase Reference: (S)-N4-BENZYL-2-BENZYLPIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N4-BENZYL-2-BENZYLPIPERAZINE(204327-96-8)
• EPA Substance Registry System: (S)-N4-BENZYL-2-BENZYLPIPERAZINE(204327-96-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 204327-96-8(Hazardous Substances Data)

Usage

General Description

"(S)-N4-Benzyl-2-Benzylpiperazine" is a chemical compound that belongs to the group of piperazine derivatives. It contains a piperazine ring with two benzyl groups attached to it. (S)-N4-BENZYL-2-BENZYLPIPERAZINE is commonly used in the field of medicinal chemistry for the development of new drugs, particularly in the area of central nervous system disorders. It exhibits pharmacological activities such as serotonin receptor agonism and dopamine receptor antagonism, making it a potential candidate for the treatment of conditions such as anxiety, depression, and schizophrenia. Additionally, it has been studied for its potential use as a precursor in the synthesis of other pharmaceutical compounds. Overall, "(S)-N4-Benzyl-2-Benzylpiperazine" is an important chemical with various potential applications in the pharmaceutical industry.

InChI:InChI=1/C18H22N2/c1-3-7-16(8-4-1)13-18-15-20(12-11-19-18)14-17-9-5-2-6-10-17/h1-10,18-19H,11-15H2/t18-/m1/s1

Upstream product

• 100-46-9 benzylamine 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 2382-86-7 methyl (S)-2-(2-chloroacetamido)-3-phenylpropanoate 
• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 
• 63-91-2 L-phenylalanine 
• 174799-52-1 tert-butyl {2-[benzylamino]ethyl}carbamate 
• 100-52-7 benzaldehyde 
• 211506-73-9 N^α-Boc-Phe-N^α-benzylglycine ethyl ester 
• 6436-90-4 ethyl 2-(benzylamino)acetate 
• 169447-84-1 (3S)-1,3-dibenzylpiperazine-2,5-dione 

Downstream Products

• 169447-86-3 tert-butyl (S)-2-benzylpiperazine-1-carboxylate 
• 1361220-69-0 2-(4-((2S)-2,4-dibenzyl-1-piperazinyl)phenyl)-1,1,1-trifluoro-2-propanol 
• 1018829-33-8 (2S)-2,4-dibenzyl-1-(4-bromo-3-methylphenyl)piperazine 
• 1009093-41-7 C₅₂H₆₇N₅O₆ 

Relevant articles and documents

Structure-Activity Relationship Studies on Oxazolo[3,4- a]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent in Vivo Activity

Neuropeptide S modulates important neurobiological functions including locomotion, anxiety, and drug abuse through interaction with its G protein-coupled receptor known as neuropeptide S receptor (NPSR). NPSR antagonists are potentially useful for the treatment of substance abuse disorders against which there is an urgent need for new effective therapeutic approaches. Potent NPSR antagonists in vitro have been discovered which, however, require further optimization of their in vivo pharmacological profile. This work describes a new series of NPSR antagonists of the oxazolo[3,4-a]pyrazine class. The guanidine derivative 16 exhibited nanomolar activity in vitro and 5-fold improved potency in vivo compared to SHA-68, a reference pharmacological tool in this field. Compound 16 can be considered a new tool for research studies on the translational potential of the NPSergic system. An in-depth molecular modeling investigation was also performed to gain new insights into the observed structure-activity relationships and provide an updated model of ligand/NPSR interactions.

Enantiomerically pure piperazines via NaBH4/I2reduction of cyclic amides

Enantiomerically pure (3S,7R,8aS)-3-phenyloctahydropyrrolo[1,2-a]pyrazine-7-ol, (3S,7R,8aS)-3-methyl octahydropyrrolo[1,2-a]pyrazine-7-ol, (3S,7R,8aS)-3-isopropyloctahydropyrrolo[1,2-a]pyrazine-7-ol and (3S,7R,8aS)-3-isobutyloctahydropyrrolo[1,2-a]pyrazine-7-ol 16d were synthesized via preparation of the corresponding cyclic amides from enantiomerically pure L-proline and hydroxyproline derivatives followed by reduction using sodium borohydride-iodine.

Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists

The 5-HT2C receptor has been implicated as a critical regulator of appetite. Small molecule activation of the 5-HT2C receptor has been shown to affect food intake and regulate body weight gain in rodent models and more recently in hu